Over time, fundamentals drive equity valuations
Biomarker Citrulline Effect Size (Typical) Longevity Translation (The So What?) FMD (Endothelial Function) +1.8% to +2.3% increase in dilation ~1626% reduction in CV event risk.(Context: Every 1% drop in FMD is associated with a 13% increase in future cardiovascular event risk.) PWV (Arterial Stiffness) -0.7 to -1.1 m/s reduction (slowing) ~1015% reduction in all-cause mortality.(Context: Every 1 m/s increase in PWV typically correlates with a 15% higher risk of CV mortality and all-cause death.) Blood Pressure -6 to -10 mmHg (Systolic) in hypertensives ~20% reduction in stroke risk.(Context: A 10 mmHg drop in systolic BP is universally accepted to lower stroke risk by ~27% and coronary heart disease by ~17%.) Note: These are theoretical risk reductions derived from biomarker improvements
Tirzepatide in Dallas, Little Elm/Frisco, TX: In recent years, there has been a significant shift in the healthcare industry, especially regarding weight loss and diabetes management
The method of claim 1 , wherein the patient is a male patient, the sexual dysfunction is erectile dysfunction, the quantity of PDE-5 inhibitor administered and the quantity of PT-141 administered together is sufficient to initiate the desired pharmacological response in the patent and less than the quantity of either PDE-5 inhibitor administered as a monotherapy or PT-141 administered as a monotherapy to treat sexual dysfunction, and the quality of erection score is superior to that obtained from administration of a therapeutically effective amount of a single agent, administered as monotherapy, sufficient to initiate the desired pharmacological response in the patent
The full ADA Standards of Care are posted here
